

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PG3416US2	SERIAL NO. 10/071,358
	APPLICANT Carter, et al.	
	FILING DATE	GROUP 1624

1046 U.S. PTO  
 10/071358  
 02/08/02

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
TNT	A1	5,654,307	8/5/97	Bridges, et al.	514	258	
	A2	4,166,735	9/97	Pilgram, et al.	71	118	
	A3	5,710,158	1/20/98	Meyers, et al.	514	289	
TNT	A4	5,773,476	6/30/98	Chen, et al.	514	620	

Continue on page 2

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
TNT	✓	B1. 86/06718	11/86	PCT			
	✓	B2. 93/17682	9/93	PCT			
	✓	B3. 93/18035	9/93	PCT			
	✓	B4. 0 370 704 B1	5/90	Europe			
	✓	B5. 0 452 002 A2	10/91	Europe			
	✓	B6. 0534 341 A1	3/93	Europe			
	✓	B7. 93/13097	6/8/93	PCT			
	✓	B8. 95/00511	1/5/95	PCT			
TNT	✓	B9. 98/14451	4/9/98	PCT			

Continue on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

TNT	✓	C1	Zydowsky et al., "Synthesis and In Vitro Evaluation of Fused Ring Heterocycle-Containing Angiotensin II Antagonists", 1994, Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 1, pp. 173-176.
	✓	C2	Robba et al., "Thienopyrimidines—II Etude De La Thieno [3,2-d] Pyrimidine et de Quelques Derives", 1971, Tetrahedron Vol. 27, pp 487-499.
	✓	C3	Hunter, "A Thousand and One Protein Kinases", Cell, Vol. 50, pp. 823-829, 1991.
	✓	C4	Modjtahedi et al., "EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN", May 14, 1998, International Journal of Oncology, Vol. 13, pp. 335-342.
	✓	C5	Hung et al., "Basic Science of HER-2/neu: A Review", August 1999, Seminars in Oncology, Vol. 26, No. 4, Suppl. 12, pp. 51-59.
	✓	C6	J.R. Woodburn, "The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy", 1999, Pharmacol Ther., Vol. 82, Nos. 2-3, pp. 241-250.
	✓	C7	Ullrich et al., "Signal Transduction by Receptors with Tyrosine Kinase Activity", April 20, 1990, Cell, Vol. 61, pp. 203-212.
	✓	C8	Bridges et al, "Tyrosine Kinase Inhibitors", J MED. CHEM., Vol. 39, No. 1, January 5, 1996, pp. 267-276.
	✓	C9	Rewcastle et al., "Tyrosine Kinase Inhibitors", J. MED. CHEM., Vol. 38, No. 18, 1995, pp. 3482-3487.
TNT	✓	C10	G.W. Rewcastle et al., "Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor", Journal of Medicinal Chemistry, 1996, Vol. 39, No. 9, pp. 1823-1835.

Continue on page 2

EXAMINER 	DATE CONSIDERED 5/22/03
---	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PG3416US2	SERIAL NO. 10/071, 358
	APPLICANT Carter, et al.	
	FILING DATE	GROUP 1624

## U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
TNT	A5 ✓ 5,789,427	8/4/98	Chen, et al.	514	352	
	A6 ✓ 5,480,883	1/2/96	Spada, et al.	514	249	
	A7 ✓ 5,646,153	7/8/97	Spada, et al.	514	259	
TNT	A8 ✓ 5,457,105	10/10/95	Barker	514	234.5	

Continue on page 3

## FOREIGN PATENT DOCUMENTS


	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
TNT	B10 97/18212 ✓	5/22/97	PCT			
	B11 0 414 386 ✓	2/27/91	Europe			
	B12 43 08 014 ✓	9/15/94	DE			
	B13 94/04526 ✓	3/3/94	PCT			
	B14 97/30034 ✓	8/1997	PCT			
	B15 97/03069 ✓	1/1997	PCT			
	B16 96/16960 ✓	6/1996	PCT			
	B17 96/15118 ✓	5/1996	PCT			
TNT	B18 96/09294 ✓	3/1996	PCT			

Continue on page 3

## OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

TNT ✓	C11	Y. Katsura et al., "Studies on antiulcer drugs. V. Synthesis and antiulcer activity of aralkylbenzozoles", Chemical and Pharmaceutical Bulletin, 1992, Vol. 40, No. 8, pp. 2062-2072.
	C12	T. Shoda et al., "Studies on antidiabetic agents. II. Synthesis of 5-[4-(methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione and its derivatives", Chemical and Pharmaceutical Bulletin, 1982, Vol. 30, pp. 3580-3600.
	C13	G.W. Rewcastle et al., "Synthesis of 6-substituted pyrido[3,d-d]pyrimidine-4(3H)-ones via directed lithiation of 2-substituted 5-aminopyridine derivatives", Journal of the Chemical Society, Perkins Transactions1., 1996, pp. 2221-2226.
	✓C14	A.F. Wilks, Progress in Growth Factor Research, 1990, 2, pp. 97-111
	✓C15	S.A. Courtneidge, Dev. Supp. I, 1993, pp. 57-64
	✓C16	J.A. Cooper, Semin. Cell Biol., 1994, 5(6), pp. 377-387.
	✓C17	R.F. Paulson, Semin. Immunol., 1995, 7(4), pp. 267-277.
	✓C18	A.C. Chan, Curr. Opin. Immunol., 1996, 8(3), pp. 394-401.
	✓C19	Dvir et al., J. Cell. Biol., 1991, 113, pp. 857-865.
	✓C20	Buchdunger et al., Proc. Natl. Acad. Sci. USA; 1991, 92, pp. 2558-2562.
	✓C21	Klausner and Samelson, Cell; 1991, 64, pp. 875-878.
	✓C22	Berkois, Blood; 1992, 79(9), pp. 2446-2454.
	✓C23	Salari et al., FEBS; 1990, 263(1), pp. 104-108.
TNT ✓	C24	Ohmichi et al., Biochemistry, 1992, 31, pp. 4034-4039.

Continue on page 3

EXAMINER 	DATE CONSIDERED 5/22/03
---	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PG3416US2	SERIAL NO. 10/071, 358
	APPLICANT Carter, et al.	
	FILING DATE	GROUP 1624

## U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
TNT	A9	5,616,582	Barker	514	234.5	
TNT	A10	4,074,057	Kawamatsu, et al.	560	55	

Continue on page \_\_\_\_\_

## FOREIGN PATENT DOCUMENTS


	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
TNT	B19	95/15758	PCT			
	B20	0 566 226	EPO			
	B21	95/19774	PCT			
	B22	97/13771	PCT			
	B23	95/24190	PCT			
	B24	96/40142	PCT			
	B25	98/02437	PCT			
	B26	98/02438	PCT			
TNT	B27	98/02434	PCT			

Continue on page \_\_\_\_\_

## OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

TNT	C25	L.K. Shawyer, DDT, 1997, 2(2), pp. 50-63.
	C26	Pharmaceutical Research, 1986, 3(6), p. 318.
	C27	C.E. Housecroft et al., Inorg. Chem., 1991, 30(1), pp. 125-130.
	C28	H. Sato et al., Bioorganic and Medicinal Chemistry Letters, 1995, 5(3), pp. 233-236.
	C29	J. Org. Chem., 1990, 55, pp.1379-90.
	C30	Helv. Chim. Acta., 1983, 66(4), p. 1046.
	C31	T.R. Kelly and F. Lang, Tetrahedron Lett., 36, 9293, 1995.
	C32	J. Chem. Soc., Chem. Commun., 1988, p. 560.
	C33	V.P. Semenov and A.N. Studenikov, "Synthesis of 7-iodo-4-aminoquinoline derivatives", Khim Geterotsikl. Soedin., 1980, Issue 7, pp. 972-975.
	C34	R. Dempsey and E. Skito, Biochemistry, 30, 1991, p. 8480.
	C35	J. Org. Chem., 1992, 57(11), pp. 3126-3131.
TNT	C36	A. Lee and W-C Dai, Tetrahedron, 1997, 53(3), pp. 859-868.

Continue on page \_\_\_\_\_

EXAMINER 	DATE CONSIDERED 5/22/03
---	----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.